Leerink Swann reiterated their outperform rating on shares of Inogen, Inc (NASDAQ:INGN) in a research report report published on Wednesday, The Fly reports. Leerink Swann currently has a $120.00 target price on the medical technology company’s stock, up from their previous target price of $115.00. Leerink Swann also issued estimates for Inogen’s Q4 2017 earnings at $0.18 EPS, Q1 2018 earnings at $0.31 EPS, Q2 2018 earnings at $0.44 EPS, Q3 2018 earnings at $0.42 EPS, Q4 2018 earnings at $0.30 EPS, FY2018 earnings at $1.47 EPS, FY2019 earnings at $1.44 EPS, FY2020 earnings at $1.98 EPS and FY2021 earnings at $2.39 EPS.

Other equities analysts have also issued reports about the stock. Needham & Company LLC reiterated a buy rating and issued a $108.00 price target on shares of Inogen in a research note on Friday, September 1st. BidaskClub lowered shares of Inogen from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Zacks Investment Research lowered shares of Inogen from a strong-buy rating to a hold rating in a research note on Tuesday, July 11th. Finally, Piper Jaffray Companies reiterated a hold rating and issued a $90.00 price target on shares of Inogen in a research note on Tuesday, September 12th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and two have given a strong buy rating to the company. Inogen presently has a consensus rating of Buy and a consensus price target of $103.14.

Shares of Inogen (NASDAQ INGN) traded down $5.53 during trading hours on Wednesday, reaching $114.19. 238,300 shares of the company traded hands, compared to its average volume of 168,926. The firm has a market capitalization of $2,383.15, a PE ratio of 92.84, a price-to-earnings-growth ratio of 4.80 and a beta of 0.99. Inogen has a 52-week low of $59.84 and a 52-week high of $124.90.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.04. The company had revenue of $69.00 million for the quarter, compared to analyst estimates of $63.55 million. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The firm’s revenue was up 26.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.25 earnings per share. sell-side analysts predict that Inogen will post 1.19 EPS for the current fiscal year.

WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/11/12/leerink-swann-reaffirms-outperform-rating-for-inogen-inc-ingn.html.

In related news, Director Raymond Huggenberger sold 14,000 shares of Inogen stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $91.67, for a total value of $1,283,380.00. Following the transaction, the director now directly owns 7,808 shares in the company, valued at approximately $715,759.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Matt Scribner sold 2,500 shares of Inogen stock in a transaction on Friday, August 18th. The shares were sold at an average price of $92.45, for a total transaction of $231,125.00. Following the completion of the transaction, the executive vice president now owns 6,964 shares in the company, valued at $643,821.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 67,000 shares of company stock worth $6,424,010. Insiders own 5.31% of the company’s stock.

A number of large investors have recently bought and sold shares of INGN. Schroder Investment Management Group acquired a new stake in Inogen in the second quarter valued at $132,000. Ameritas Investment Partners Inc. lifted its holdings in Inogen by 6.1% in the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after acquiring an additional 86 shares during the period. Sei Investments Co. lifted its holdings in Inogen by 38.1% in the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after acquiring an additional 443 shares during the period. Victory Capital Management Inc. lifted its holdings in Inogen by 17.8% in the second quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock valued at $194,000 after acquiring an additional 307 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Inogen in the first quarter valued at $203,000.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

The Fly

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.